Clinical trials: Depressive State
Schizophrenia, Affective Symptoms
Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary
This is a noninterventional observational study lead amongst psychiatrists, to assess the the overall status of schizophrenic outpatients with affective symptoms treated with atypical antipsychotics.
- Trial name
- AFFECT (NCT01534936)
- Where
- 53 sites in Hungary
- Volunteers
- 2,153 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.
- Trial name
- NCT00072774
- Testing
- DVS-233 SR
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Psoriatic Arthritis
Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis
This is an epidemiological non-interventional study assessing the prevalence of anxiety and/or depression disorders in patients suffering from Psoriatic Arthritis (PsA) in Spain.
- Trial name
- NCT00884468
- Where
- Spain
- Volunteers
- 384 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder
This study is to evaluate that (SEROQUEL®) quetiapine sustained-release is efficacious and safe in the treatment of patients with MDD.
- Trial name
- MOONSTONE (NCT00320268)
- Testing
- Quetiapine fumarate
- Where
- 37 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Depression, Anxiety, IBS - Irritable Bowel Syndrome
Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)
Viome costumers are consented and recruited for this study and complete the questionnaires upon enrollment. Any participant who previously self reported depression, anxiety, or Irritable Bowel Syndrome (IBS) qualify for this…
- Trial name
- NCT04905524
- Testing
- VIOME Precision Nutrition Program
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Viome
Bipolar Depression, Major Depressive Disorder
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
This is a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of lumateperone monotherapy in the treatment of patients with major depressive episodes associated with Bipolar I or…
- Trial name
- NCT04285515
- Testing
- Lumateperone
- Where
- 42 sites in United States, Bulgaria and 3 more
- Volunteers
- 488 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Treatment Resistant Depression (TRD)
Ketamine Biomarker Validation
An EEG-based biomarker will be developed for the effects of ketamine infusion in patients with Depression. The effects of ketamine infusion on Depression symptoms and EEG signals will be analyzed.
- Trial name
- NCT07307768
- Testing
- Ketamine (0.25 mg/kg), Ketamine (0.5 mg/kg), Ketamine (0.75 mg/kg)
- Where
- United States
- Sponsor
- Soterix Medical
Depressive Disorder, Major
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment
The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI)…
- Trial name
- ESCAPE-LTE (NCT04829318)
- Testing
- Esketamine, SSRI/SNRI
- Where
- 59 sites in Argentina, Belgium and 12 more
- Volunteers
- 183 people
- Sponsor
- Janssen-Cilag Ltd.
Suicide Ideation, Suicidal Intention
Classification and Assessment of Mental Health Performance Using Schematics
This is an open enrollment study to collect data for the optimization of smartphone-based algorithms for the early detection of mental health and suicidal risk in a student population.
- Conditions
- Suicide Ideation, Suicidal Intention, Suicide and Depression
- Trial name
- CAMPUS (NCT04275908)
- Testing
- MHSAFE app
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Clarigent Health
Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-controlled, multicenter randomized withdrawal trial in patients with major…
- Trial name
- CLARITY (NCT07484217)
- Testing
- Solriamfetol 150 MG
- Where
- 40 sites in United States
- Volunteers
- 508 people
- Sponsor
- Axsome Therapeutics, Inc.
Depression
Pharmacogenetic-Directed Treatment for Major Depression
Determine if antidepressant treatment guided by pharmacogenetic algorithm and interpretive report improves outcomes when compared with standard treatment without the availability of genetic information.
- Trial name
- NCT01261364
- Testing
- GeneSightRx, Treatment as usual
- Volunteers
- 50 people
- Sponsor
- Assurex Health Inc.
Bipolar Depression
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as…
- Trial name
- NCT06372964
- Testing
- Lumateperone
- Where
- 68 sites in United States, Colombia and 2 more
- Volunteers
- 384 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life After the Administration of ImmunoVita® in Chronic Fatigue Syndrome Patients
Chronic Fatigue Syndrome, also known as Myalgic Encephalomyelitis (CFS / MS) is a medical entity characterized mainly by debilitating and prolonged fatigue lasting more than 6 months, post-exertion fatigue (physical and / or…
- Trial name
- NCT04301609
- Testing
- Active
- Where
- Spain
- Volunteers
- 67 people
- Sponsor
- Vitae Health Innovation
Major Depressive Disorder
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive control.
- Trial name
- PHOENIX (NCT00252330)
- Testing
- SR58611A
- Where
- 2 sites in United States, Canada
- Volunteers
- 476 people
- Sponsor
- Sanofi
Depression, Depressive Disorder
Digital Therapeutic for Adolescent Depressive Symptoms in Hematology, Oncology, and Weight Management
The primary aims of the proposed research are to assess the feasibility, acceptability, and preliminary evidence of efficacy of a self-guided, cognitive behavioral therapy (CBT)-based mobile app intervention (SparkRx) for the…
- Conditions
- Depression, Depressive Disorder, Depressive Symptoms, Depressive Episode
- Trial name
- NCT05351866
- Testing
- CBT-based mobile intervention for depression, Mobile control with education about depression
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Limbix Health, Inc.
Treatment Resistant Depression
Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
This study will evaluate the efficacy and safety of NV-5138 in adults with TRD
- Trial name
- NCT05066672
- Testing
- NV-5138
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Navitor Pharmaceuticals, Inc.
Depressive Disorder, Major
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
This is a Phase 1, conventional, double-blind, placebo-controlled, single-center clinical study comprised of 2 segments (Segment 1 and Segment 2) in which single and multiple doses of SUVN-911 or placebo will be orally…
- Trial name
- SUVN-911 (NCT03155503)
- Testing
- SUVN-911
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Suven Life Sciences Limited
Treatment Resistant Depression, Major Depressive Disorder
Mechanistic Evaluation of Response in TRD (MERIT)
To evaluate the relapse prevention of AXS-05 relative to placebo in subjects with treatment resistant depression (TRD). This is a randomized, double-blind, placebo-controlled study to evaluate AXS-05 compared to placebo in…
- Trial name
- MERIT (NCT04608396)
- Testing
- AXS-05
- Where
- 20 sites in United States
- Volunteers
- 44 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Flexible Dose Titration Add-on Study to Treat Major Depressive Disorder
Depressed patients will receive 6 weeks of citaloprma (20-40mg) therapy. Subjects who have an inadequate response (partial or non-responder) will be randomized to receive either mecamylamine (5-10mg) or placebo added to their…
- Trial name
- NCT00593879
- Testing
- Mecamylamine
- Volunteers
- 450 people
- Sponsor
- Targacept Inc.
Major Depressive Disorder
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
The primary purpose of your participation in this study is to help answer the following research question: Whether 12-week administration of EMSAM (selegiline transdermal system) is safe and effective for the treatment of…
- Trial name
- NCT00531947
- Testing
- Selegiline Transdermal System
- Where
- 20 sites in United States
- Volunteers
- 308 people
- Sponsor
- Somerset Pharmaceuticals